Parkiet: Bioceltix has been developing its own pharmaceuticals since 2016. It is also one of the first companies in Europe to complete a full EMA registration path for a medicinal product that uses mesenchymal stem cells (MSC) as an active substance. The therapies created by Bioceltix are supposed to be a safer alternative to current synthetic drugs.
